Likewise, assessment of splenic NK cells from panobinostat-treated tumor-bearing mice also showed a significant increase in the percentage of CD107a+ NK cells, as well as positive for CD69, a surface marker related NK cell activation, when compared to the control. The gene discussed is LAMP1; the disease is neoplasm.